GlobeNewswire

Casa Systems to Showcase Innovative Core and Access Solutions that Transform All Broadband Networks to 5G at ANGA COM 2018

Dela

ANDOVER, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Casa Systems (Nasdaq:CASA), a leading provider of converged broadband infrastructure technology solutions for mobile, cable, fixed and converged broadband networks today announced that it will demonstrate its innovative multi-service core and access network solutions at ANGA COM, June 12-14 in Cologne, Germany, in Hall 7, Stand #G11. In addition, Casa's product and solution experts will participate in panels that explore network convergence, discuss lessons learned with virtual CCAP and Remote PHY, and share new Wi-Fi use cases, coverage and user experiences.

"For any broadband network, at any stage of transformation, Casa Systems has the technology to help service providers step up their broadband network's potential," said Jerry Guo, CEO at Casa Systems. "Our portfolio of agile broadband solutions are engineered for the performance, flexibility and scale that cable, wireless, fixed and converged networks require for 5G."

Casa Demonstrations at ANGA COM 2018

In today's all connected world, service providers are transforming networks to increase capacity and improve agility. Casa Systems accelerates network innovation with a suite of intelligent broadband solutions that deliver the bandwidth and service agility that service providers need today with a clear path to a converged, virtualized and distributed multi-access network.  
                                                             
Distributed, Programmable and Agile HFC Network:  Casa's Axyom(TM) Virtual CCAP (vCCAP) and Distributed Access Architecture (DAA) solutions enable intelligent design and programmability throughout the next generation cable network, from the core to the edge.  Casa's Axyom vCCAP virtualizes CCAP core functions in a micro-services based software architecture and delivers multi-dimensional scaling and high performance from a lean vCPU footprint. Developed for the virtual compute environment from the ground up, the Axyom vCCAP is designed to support full interoperability in a distributed access architecture. Casa's Distributed Access solution helps service providers push capacity to the edge, leverage current investments and densify access networks to flexibly deliver video, voice and data while efficiently supporting bandwidth growth, ensuring customer satisfaction. Casa will demonstrate vCCAP interoperability using open standards with the BKtel Remote PHY module. 

5G Flexibility for Fixed Networks:  The latest addition to Casa's 5G converged software architecture, the Axyom(TM) Virtual Broadband Network Gateway (vBNG) Router solution is the industry's first virtualized broadband network gateway that delivers superior performance, multi-dimensional scaling, and flexibility needed to address the greater diversity of 5G broadband demands. At ANGA COM, Casa will showcase an integrated vBNG solution that demonstrates not only high capacity and performance, but also a unique ability to offload and distribute the data plane so service providers can better control and distribute intelligence to the network edge. 

Unified Broadband Services:  Casa's Unified Broadband Services solution provides a logical approach to meet capacity challenges by extending the life of existing HFC investments.  Casa will demonstrate the ability to deliver full DOCSIS 3.1 services (voice, video and data) over the traditional HFC network and Distributed Access Network from a single integrated CCAP chassis, which gives service providers the flexibility to target capacity where it is needed most while maximizing existing CCAP investments. 

Programmable Access Using CableLabs' Standard Models:  Native NETCONF protocol and standards-based YANG models from Casa Systems give service providers programmatic control over remote devices which reduces costs, complexity and time to market of DAA implementations.  With Casa's solutions, service providers can choose best of breed SDN controllers and NFV orchestrators with standardized Yang models, assuring interoperability.  Casa will demonstrate full MAC domain configuration of a Remote PHY device using NETCONF / Yang.

Visit Casa Systems and view these demos in Hall 7, Stand #G11 at ANGA COM.

Casa Experts to Discuss Fixed and Mobile Convergence, Fiber Deep Solutions and the Wi-Fi User Experience During Panels

  • Casa's John Knox, Principal Solution Architect for Cable Access, will talk about the lessons learned from Fiber Deep implementations during the "Future-Proofed Fiber: From the Headend to the Terminal" panel on Tuesday, June 12 at 03:00 in Room 2.
     
  • Casa's Michael DiGiorgio, Director of Product Management - Wi-Fi, will participate on the panel,  "Wi-Fi - Use Cases, Coverage and User Experience" on Thursday, June 14 at 11:30, Room 2. The panel will discuss how to manage the Wi-Fi experience to deliver revenue and enhance security.  
     
  • Casa's Peter Wolff, Manager, Solutions Architect Group, will talk about delivering fixed and mobile convergence solutions with a common software platform at the "SDN & NFV - Enabling Fixed and Mobile Convergence" panel on Thursday, June 14 at 01:00, Room 2. 

About Casa Systems, Inc.
Casa Systems, Inc. (Nasdaq:CASA) delivers converged broadband technology solutions that enable mobile, cable and fixed network service providers to meet the growing demand for gigabit bandwidth and services. Our suite of distributed and virtualized solutions for fixed and mobile 5G ultra-broadband networks are engineered for performance, flexibility and scale. Commercially deployed in over 70 countries, Casa serves more than 450 Tier 1 and regional service providers worldwide.

For more information, please visit us at http://www.casa-systems.com.                                                          

CONTACT INFORMATION:

Alicia Thomas
Casa Systems, Inc.
100 Old River Road
Andover, Mass. 01810
+1.817.909.8921
alicia.thomas@casa-systems.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Casa Systems, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum